Richard B. Warren, Yukari Okubo, Milan Anadkat, Peter Wolf, Binqi Ye, S. Renée Marshall, Christian Thoma, Min Zheng
{"title":"43754 Efficacy and safety of spesolimab for the treatment of generalized pustular psoriasis flares in hospitalized versus non-hospitalized patients","authors":"Richard B. Warren, Yukari Okubo, Milan Anadkat, Peter Wolf, Binqi Ye, S. Renée Marshall, Christian Thoma, Min Zheng","doi":"10.1016/j.jaad.2023.07.171","DOIUrl":null,"url":null,"abstract":"Generalized pustular psoriasis (GPP) is a rare skin disease associated with excess hospital admissions. In Effisayil 1 (NCT03782792), spesolimab treatment led to rapid pustular and skin clearance, with a favorable safety profile, in patients with GPP flares. We report the efficacy and safety of spesolimab in hospitalized and non-hospitalized patients. Overall, 51/53 patients in Effisayil 1 had hospitalization data: 25 (spesolimab, 17; placebo, 8) were hospitalized due to a GPP flare at randomization (median length of stay, 8.0 days); 26 were not hospitalized (spesolimab, 16; placebo, 10). Baseline demographics were similar between spesolimab and placebo treatment groups independent of hospitalization status.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"25 1","pages":"0"},"PeriodicalIF":11.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jaad.2023.07.171","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Generalized pustular psoriasis (GPP) is a rare skin disease associated with excess hospital admissions. In Effisayil 1 (NCT03782792), spesolimab treatment led to rapid pustular and skin clearance, with a favorable safety profile, in patients with GPP flares. We report the efficacy and safety of spesolimab in hospitalized and non-hospitalized patients. Overall, 51/53 patients in Effisayil 1 had hospitalization data: 25 (spesolimab, 17; placebo, 8) were hospitalized due to a GPP flare at randomization (median length of stay, 8.0 days); 26 were not hospitalized (spesolimab, 16; placebo, 10). Baseline demographics were similar between spesolimab and placebo treatment groups independent of hospitalization status.
期刊介绍：
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
